Company profile
NKGen Biotech, Inc.
OTC: NKGN · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 1GM —SS 30
v0.1 · 25/100 weight · pillars only
↑ Piotroski F, workforce scale · ↓ revenue growth (YoY), disclosure history
Methodology →Revenue TTM
$652.0k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$44.3M
Employees
26
as of 2026-08-23
Market cap
$666.1k
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02023
Net income-$44.3M-$44.3M2024
Operating income-$27.0M-$27.0M2024
Total assets$16.2M$16.2M2024
Liabilities$86.1M$86.1M2024
Equity-$69.9M-$69.9M2024
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is NKGen Biotech, Inc.’s revenue?
NKGen Biotech, Inc. booked $0 in FY2023 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Genix Pharmaceuticals Corporation——Pharmadrug Inc.——Agentix Corp.17DChitogenX Inc.——Hepion Pharmaceuticals, Inc.24D4Cable TV International, Inc.——Neighbors
Orange →Key facts
CEOPaul Y. Song
SectorHealthcare
IndustryBiotechnology
HeadquartersSanta Ana, CA
ExchangeOTC: NKGN
Employees26
IPO date2021-07-13
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.